Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)
Naila Shaheen,Ibrahim Abosoudah,Mohammad Alshahrani,Mohsen Alzahrani,Mohammed Essa,Bader Alahmari,Enas Mutaher,Solaf Kanfar,Ahmad Alsaeed,Sameer Alamoudi,Dania Monagel,Mohammed Marei,Musa Alzahrani,Abdulrahman Alsultan,Abdullah Aljefri,Ahlam Masari,Omer Alsharif,Ammar H. Alsughayir,Ayman Hejazi,Saad Aldaama,Ahmed Alaskar
DOI: https://doi.org/10.1038/s41409-024-02240-3
2024-03-09
Bone Marrow Transplantation
Abstract:Hematopoietic Cell Transplantation (HCT) activity was surveyed in the Kingdom of Saudi Arabia (KSA). The overall rate of HCT per 10,000,000 inhabitants doubled every 10 years. 15,031 HCTs were reported by all the functional HCT centers in KSA since inception of HCT program. Out of total HCT 15,031; 10,232(68%) were reported in adults, and 4799(32%) in the pediatric population. Allogeneic HCT constituted 10,489(70%) of total HCT, with majority from Human Leukocyte Antigen matched identical sibling (85.4%). The autologous HCTs were 4542(30%). During the last five years 2018–2022; in total 5164 HCTs were performed, with the majority had allogeneic HCT 3,085(59.74%), followed by the autologous HCT 3085(40.2%). The top three main indications of the autologous HCT were Multiple Myeloma 299(28%), Hodgkin Lymphoma 293(27.8%), and Non-Hodgkin Lymphoma 212(20%). Hemoglobinopathies 615(27.6%) were mostly indicated for allogeneic HCT, followed by Acute Myeloid Leukemia 433(19.4%), and Precursors Lymphoid Neoplasms 322(14.4%). The HCT activity landscape survey provides the updated current state and trends for HCT in KSA. The reported HCT numbers differ than what was reported by international registries, since not all the cases have been reported. We urge to have a common data hub nationally in order to capture the actual number of cases.
oncology,immunology,hematology,transplantation